Clinical Trial Detail

NCT ID NCT03178071
Title Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer Harboring Specific Molecular Alterations
Recruitment No longer available
Gender both
Phase Expanded access
Variant Requirements yes
Sponsors Pfizer
Indications

lung non-small cell carcinoma

Therapies

Lorlatinib

Age Groups: adult senior

Additional content available in CKB BOOST